Search
Influenza B virus B/Phuket/3073/2013 live (attenuated) antigen
go.drugbank.com/drugs/DB11036ApprovedInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Chlormerodrin
go.drugbank.com/drugs/DB00534ApprovedWithdrawnChlormerodrin is a mercurial compound with toxic side effects that was previously used as a diuretic. The radiolabeled form has been used as a diagnostic and research tool. It is no longer used and has been replaced with new classes of d...
CP-778875
go.drugbank.com/drugs/DB19211InvestigationalCP-778875 is under investigation in clinical trial NCT00326326 (Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.).
Copper Cu-64
go.drugbank.com/drugs/DB13980Approved[T604] It is used in molecular radiotherapy and positron emission tomography. … Copper-64 is a radiopharmaceutical usually found in the +2 oxidation state as the complexes including the +1 state tend to be more unstable.
AM365
go.drugbank.com/drugs/DB06564ExperimentalDetiviciclovir (AM365) is an antiviral nucleoside analogue.
Nicotinamide riboside
go.drugbank.com/drugs/DB14933ApprovedInvestigationalWithdrawnNicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis).
Ochromycinone
go.drugbank.com/drugs/DB15644InvestigationalOchromycinone is under investigation in clinical trial NCT01047943 (STA-21 Topical Efficacy on Psoriasis).
Carlumab
go.drugbank.com/drugs/DB12718ApprovedWithdrawnCarlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
ISA101b
go.drugbank.com/drugs/DB18694InvestigationalISA101b (peltopepimut-S) is a therapeutic vaccine against the HPV-specific E6/E7 oncoproteins.
IR501
go.drugbank.com/drugs/DB06464ExperimentalIt was last known to be in phase III clinical trials. … IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity.